Stada And Xbrane Win EU Endorsement For Ranibizumab
Ximluci, Third Biosimilar Rival To Lucentis, Receives Positive Opinion From CHMP
• By David Wallace
Stada and Xbrane are eyeing the third European biosimilar ranibizumab approval • Source: Shutterstock 
